CORCEPT THERAPEUTICS INC
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
CORT$75.03+3.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31,2025 | December 31,2024 | |
|---|---|---|
| (Unaudited) | (See Note 1) | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $89,819 | $127,665 |
| Short-term marketable securities | 232,944 | 255,669 |
| Trade receivables, net of allowances | 61,819 | 53,976 |
| Inventory | 14,368 | 12,412 |
| Prepaid expenses and other current assets | 39,553 | 21,880 |
| Total current assets | 438,503 | 471,602 |
| Strategic inventory | 1,166 | 3,583 |
| Operating lease right-of-use asset | 5,147 | 5,324 |
| Property and equipment, net | 2,543 | 2,689 |
| Long-term marketable securities | 248,041 | 219,831 |
| Other assets | 6,610 | 6,610 |
| Deferred tax assets, net | 144,445 | 130,914 |
| Total assets | $846,455 | $840,553 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $27,947 | $15,376 |
| Accrued research and development expenses | 25,260 | 33,868 |
| Accrued and other liabilities | 88,875 | 90,700 |
| Short-term operating lease liability | 984 | 829 |
| Total current liabilities | 143,066 | 140,773 |
| Long-term operating lease liability | 5,851 | 6,107 |
| Long-term accrued income taxes payable | 14,253 | 14,084 |
| Total liabilities | 163,170 | 160,964 |
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Preferred stock | — | — |
| Common stock | 137 | 136 |
| Treasury stock | (744,692) | (696,173) |
| Additional paid-in capital | 862,866 | 832,108 |
| Accumulated other comprehensive income (loss) | 692 | (217) |
| Retained earnings | 564,282 | 543,735 |
| Total stockholders’ equity | 683,285 | 679,589 |
| Total liabilities and stockholders’ equity | $846,455 | $840,553 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.